Compare AbbVie Inc (ABBV) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs AngloGold Ashanti Limited — how do they compare? AbbVie Inc trades at $247.84 (market cap $438.19B), while AngloGold Ashanti Limited trades at $96.17 (market cap $49.19B). The key difference: AbbVie Inc is far larger — about 8.9× AngloGold Ashanti Limited's market cap, and AngloGold Ashanti Limited pays the higher dividend (4.65%). Which is the better fit depends on your goals.
| ABBV | AU | |
|---|---|---|
Market Cap | $438.19B | $49.19B |
Sector | Health | Basic Materials |
52-Week High | $263.58 | $128.26 |
52-Week Low | $197.38 | $52.15 |
Enterprise Value | $502.45B | $48.20B |
Dividend Yield | 2.79% | 4.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.44, up 0.57% today, with a bullish technical signal and strong support near $243. The company reported revenue of $61.16B in 2025, with net income of $4.23B, and has beaten EPS estimates for three consecutive quarters. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying interest.
Outlook remains positive with a consensus price target of $281.33, though high P/E of 70.05 and looming patent cliffs in the 2030s present risks. Revenue growth is driven by Skyrizi and Rinvoq, offsetting Humira declines, supporting a buy-rated stance amid cautious optimism for sustained expansion.
AngloGold Ashanti (AU) surged 9.85% to $96.22 on strong gold price momentum and positive Q2 earnings. The stock trades near its 52-week high with bullish technical indicators and robust fundamentals including 26.64% net margins and 46.5% ROE. Recent quarterly results showed mixed performance with Q1 beating expectations while Q2 slightly missed, but strong free cash flow growth supports increased shareholder returns including dividends and a $2 billion buyback program.
Outlook remains positive with analyst consensus at $120.33 target (25% upside) and 64% buy ratings. Key catalysts include H2 production growth and gold price strength, while risks involve operational disruptions and commodity volatility. The company's improving balance sheet and cash generation support continued dividend payments and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
